From Current Contents to Open Access Journals

Jan F. Vojáček

Interv Akut Kardiol. 2016;15(2):67-70  

Padesát let od zahájení akutní koronární péče v České republice

Vladimír Staněk

Interv Akut Kardiol. 2016;15(2):71-72  

Occurrence and prognosis of patients with persistent left superior vena cava in pacemaker implantation

David Šipula, Jiří Plášek, Milan Kozák, Miroslav Homza

Interv Akut Kardiol. 2016;15(2):74-76 | DOI: 10.36290/kar.2016.015  

Aim: To monitor the proportion of persistent left superior vena cava patients indicated for pacemaker implantation. Methods: Baseline data of patients with PLSVC are compared with those of the reference populationvwithout the presence of PLSVC. The authors focus on differences in terms of implantation and its potential complications. Results: The authors describe the occurrence of PLSVC in six patients during a six-year implantation period. Lead placement in patients with the presence of PLSVC is a certain complication and prolongs the procedure; however, following successful lead placement in the monitored group, the authors found no difference...

Use of excimer laser atherectomy for coronary angioplasty

Martin Sluka

Interv Akut Kardiol. 2016;15(2):77-80 | DOI: 10.36290/kar.2016.016  

Excimer laser atherectomy has been used for coronary intervention for more than 20 years. During this period of time has been gradual development of the technology itself, enabling higher density energy delivery with lower heat production, leading to higher efficiency along with improvements in the procedure safety and obviously to the original indication modification using this method. Own experience with this technology is presented through a coronary angioplasty case report impossible to complete using standard approach. Laser atherectomy maintains its specific role in the treatment of complex coronary lesions, particulary in cases of...

The current state of lipid modifying therapy in the Czech population

Hana Rosolová

Interv Akut Kardiol. 2016;15(2):81-84 | DOI: 10.36290/kar.2016.017  

Hyperecholesterolemia, i.e. elevated total and LDL-cholesterol, belongs to basic modifiable risk factors of atherosclerosis and cardiovascular disease. If the patient has high or very high total cardiovascular risk, pharmacological lipid modifying therapy should be introduced; the most effective drugs are right now statins. Statin therapy is not used sufficiently. Statins are underdosed from many different reasons atributable to physician or patient. Other lipid disorders are underdiagnosed, esp. atherogenic dyslipidemia, which represents residual lipid cardiovascular risk, esp. in patients with type 2 diabetes. Level of non-HDL cholesterol...

Principles of rational antibiotic use (part I)

Pavla Paterová, Pavlína Králíčková, Petra Vávrová, Helena Žemličková

Interv Akut Kardiol. 2016;15(2):85-89 | DOI: 10.36290/kar.2016.018  

Infections are among the most common reasons for physician visits. Antibiotic comsuption a bacterial resistance increase worldwide. The aim of this article is to draw general principles of racionale antibiotic use in practical terms, to highlight some common mistakes and suggest how to avoid them.The first part focuses on the basic balance sheet physician prior to beginning treatment with antibiotics, and initial antibiotic therapy.

Principles of rational antibiotic use (part II)

Pavla Paterová, Pavlína Králíčková, Petra Vávrová, Helena Žemličková

Interv Akut Kardiol. 2016;15(2):90-93 | DOI: 10.36290/kar.2016.019  

Infections are among the most common reasons for physician visits. Antibiotic comsuption a bacterial resistance increase worldwide. The aim of this article is to draw general principles of racionale antibiotic use in practical terms, to highlight some common mistakes and suggest how to avoid them. The second part deals with the evaluation of the effectiveness of antibiotic therapy to the completion of treatment with antibiotics.

Surgical treatment of an invasive thymoma extending into the right atrium and infiltrating

Vladimíra Zdráhalová, Štěpán Černý, Tomáš Mráz, Helena Čoupková, Petr Neužil, Ivo Skalský

Interv Akut Kardiol. 2016;15(2):94-96 | DOI: 10.36290/kar.2016.020  

the pericardium, mediastinum and great vessels The authors present a case of a 48-year-old female with a malignant thymoma with intracardiac right atrium extension. Although invasive thymoma commonly infiltrates mediastinal structures, intracardiac spread is rare. The patient underwent cardiac surgery with complete removal of the endocardial neoplastic tissue. Postoperatively, the patient received adjuvant chemoradiotherapy. One year after surgery, no recurrences were seen.

Stenosis of right pulmonary artery by periprosthetic masses of ascending aorta

Jana Bucková, Štěpán Černý, Ivo Skalský, Miroslava Benešová, Jaromír Chlumský

Interv Akut Kardiol. 2016;15(2):97-99 | DOI: 10.36290/kar.2016.021  

We report the case of a 62-year-old patient with a history of aortic replacement and replacement of the ascending aorta. The perioperative finding was surprising while an active infection was excluded.

Bare metal stents are going out the same way as the dinosaurs

Ivo Varvařovský

Interv Akut Kardiol. 2016;15(2):100-101  

In a randomized, double-blind trial, drug-coated stent was compared with bare metal stent in patients with a high risk of bleeding. All patients received 1 month of dual antiplatelet therapy and were followed more than one year. Treatment with drug-coated stent led to 50 % decrease in target vessel revascularization and to 32 % decrease of myocardial infarction.

Anthracyclines and cardioprotection - focusing on the mechanism of function

Veronika Puchnerová, Zuzana Nováková, Zdeněk Wilhelm

Interv Akut Kardiol. 2016;15(2):102-105  

We can characterize anthracyclines as very important anti-tumour antibiotics with wide range of use in therapy of solid tumours and haematological diseases. Although anthracyclines are efficient in treatment of cancer, their use is quite limited by their cardiotoxic effects. In this review we are focusing on the mechanism of function of the drug, the origin of cardiotoxicity and its clinical manifestation. Then we will be talking about cardioprotection which could eliminate the damage of the heart muscle by the treatment.